ASCO's report from the Mai 16 Presscast:

  • Shorter Trastuzumab Treatment for HER2+ Breast Cancer Can Be as Effective, With Fewer Cardiac Side Effects
    ALEXANDRIA, Va. – A phase III randomized clinical trial of 4,088 women with HER2-positive, early-stage breast cancer found that taking trastuzumab (Herceptin) for 6 months was non-inferior to the current standard of 12 months.
  • Read the full release.
     
  • Use of Mobile and Sensor Technology Lowers Symptom Severity for People With Head and Neck Cancer
    ALEXANDRIA, Va. – A federally funded, randomized clinical trial of 357 people receiving radiation for head and neck cancer, using mobile and sensor technology to remotely monitor patient symptoms, resulted in less severe symptoms related to both the cancer and its treatment (both general and cancer-related). Read the full release.
     
  • Vast Majority of Heavy Smokers Not Screened for Lung Cancer Despite USPSTF Recommendations
    ALEXANDRIA, Va. – An analysis of 1,800 lung cancer screening sites nationwide found that only 1.9% of more than 7 million current and former heavy smokers were screened for lung cancer in 2016, despite United States Preventive Services Task Force (USPSTF) and ASCO screening recommendations. Read the full release.
     
  • Upfront, Comprehensive Genetic Testing in Advanced Lung Cancer Is Cost-Effective
    ALEXANDRIA, Va. – An economic model comparing different types of genetic testing in metastatic non-small-cell lung cancer (NSCLC) found that using next-generation sequencing (NGS) to test for all known lung cancer-related gene changes at the time of diagnosis was more cost-effective and faster than testing one or a limited number of genes at a time. Read the full release.
     
  • More Choices for Treating Insomnia in Cancer Survivors: Acupuncture and Cognitive Behavioral Therapy
    ALEXANDRIA, Va. – A Patient-Centered Outcomes Research Institute (PCORI)-supported randomized clinical trial of cancer survivors showed that eight weeks of either acupuncture or cognitive behavioral therapy for insomnia (CBT-I) decreased the severity of insomnia among cancer survivors, though improvements were greatest among patients receiving cognitive behavioral therapy. Read the full release.
     
  • New Regimens Improve Survival for Children and Young Adults With T-Cell Cancers
    ALEXANDRIA, Va. – In a federally funded, randomized phase III clinical trial performed by the Children’s Oncology Group (COG), 90% of children and young adults with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LL) were alive four years after starting treatment regimens on this trial, and 84% were cancer free. Read the full release.